Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676466 · ClinicalTrials.gov registry record · Phase 2
The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study
A Phase 2 study of Inflammation, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
- 5
- Study locations
NCT02676466: Completed Phase 2 study of Inflammation, sponsored by University of Florida.
NCT02676466 is a Phase 2 study of Inflammation that has completed, run by University of Florida. The registered enrollment target is 289 participants, roughly in line with the 286-participant average among 132 other Inflammation trials with a reported enrollment target. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02676466, a Phase 2 study of Inflammation, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
- 5
- Study locations
Study Summary
ENRGISE Pilot Study will test the ability of anti-inflammatory interventions for preventing major mobility disability by improving or preserving walking ability.
Primary Outcome
Changes in the Interleukin-6 Level Between the Groups
Conditions Studied
Interventions
- DRUG Losartan
- DIETARY_SUPPLEMENT Omega-3 fish oil
- OTHER Corn Oil (Fish oil Placebo)
- OTHER Cellulose Based (Losartan Placebo)
Study Locations (5)
Florida
- University of Florida - Gainesville
Illinois
- Northwestern University - Chicago
Massachusetts
- Tufts University - Boston
North Carolina
- Wake Forest University - Winston-Salem
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2016-04-26 |
| Est. Completion | 2018-06-22 |
| Phase | Phase 2 |
What the finished NCT02676466 record still lists
NCT02676466 is an interventional study that assigns participants to a tested intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 286-participant average among 132 other Inflammation trials with a reported enrollment target.
The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 4 interventions - of which Losartan is the first listed.
NCT02676466 lists 5 locations in 5 states (Florida, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT02676466 about?
NCT02676466 is a clinical study titled "The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study". ENRGISE Pilot Study will test the ability of anti-inflammatory interventions for preventing major mobility disability by improving or preserving walking ability.
What is the current status of trial NCT02676466?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2016-04-26. Estimated completion is 2018-06-22.
What conditions does trial NCT02676466 study?
This clinical trial studies the following conditions: Inflammation.
What interventions are being tested in trial NCT02676466?
The interventions under investigation include: Losartan (DRUG), Omega-3 fish oil (DIETARY_SUPPLEMENT), Corn Oil (Fish oil Placebo) (OTHER), Cellulose Based (Losartan Placebo) (OTHER).
Who is sponsoring clinical trial NCT02676466?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02676466 being conducted?
This trial has 5 study locations across Florida, Illinois, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02676466's enrollment target sits among peer trials
289 19th of 132 higher than 114 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI